Luminex’s Q4 Revenues Fall 1 Percent on Weak Assay Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that its fourth quarter revenues fell 1 percent year over year on lower assay sales.

Total revenues for the three months ended Dec. 31, 2013, were $55.2 million, down from $55.5 million in the fourth quarter of 2012. The results fell short of the consensus Wall Street estimate of $56.6 million in revenues for the quarter.

By segment, assays and related product revenue fell 25 percent to $19.5 million from $25.9 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.